Enzyme-linked immunosorbent assay using a virus type-specific peptide based on a subdomain of envelope protein e(rns) for serologic diagnosis of pestivirus infections in swine by Langedijk, J.P. et al.
JOURNAL OF CLINICAL MICROBIOLOGY,
0095-1137/01/$04.0010 DOI: 10.1128/JCM.39.3.906–912.2001
Mar. 2001, p. 906–912 Vol. 39, No. 3
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
Enzyme-Linked Immunosorbent Assay Using a Virus Type-
Specific Peptide Based on a Subdomain of Envelope Protein
Erns for Serologic Diagnosis of Pestivirus Infections in Swine
J. P. M. LANGEDIJK,1* W. G. J. MIDDEL,1 R. H. MELOEN,2 J. A. KRAMPS,3 AND J. A. DE SMIT1
Department of Mammalian Virology,1 and Department of Production,3 Institute for Animal Science and Health
(ID-Lelystad), and Pepscan Systems B.V.,2 Lelystad, The Netherlands
Received 7 July 2000/Returned for modification 8 September 2000/Accepted 17 October 2000
Peptides deduced from the C-terminal end (residues 191 to 227) of pestivirus envelope protein Erns were used
to develop enzyme-linked immunosorbent assays (ELISAs) to measure specifically antibodies against different
types of pestiviruses. The choice of the peptide was based on the modular structure of the Erns protein, and the
peptide was selected for its probable independent folding and good exposure, which would make it a good
candidate for an antigenic peptide to be used in a diagnostic test. A solid-phase peptide ELISA which was
cross-reactive for several types of pestivirus antibodies and which can be used for the general detection of
pestivirus antibodies was developed. To identify type-specific pestivirus antibodies, a liquid-phase peptide
ELISA, with a labeled, specific classical swine fever virus (CSFV) peptide and an unlabeled bovine viral
diarrhea virus peptide to block cross-reactivity, was developed. Specificity and sensitivity of the liquid-phase
peptide ELISA for CSFV were 98 and 100%, respectively. Because the peptide is a fragment of the Erns protein,
it can be used to differentiate between infected and vaccinated animals when a vaccine based on the E2 protein,
which is another pestivirus envelope protein, is used.
Classical swine fever virus (CSFV), Bovine viral diarrhea virus
(BVDV), and Border disease virus (BDV) belong to the genus
Pestivirus of the Flaviviridae family (7). CSFV is restricted to
swine, whereas BVDV and BDV have been isolated from
several species such as cattle, swine, sheep, deer, and giraffes
(17). Although pigs can be infected by all these pestiviruses
(17, 22), only CSFV induces severe disease and is often fatal.
The disease is characterized by fever and leukopenia and can
run an acute, chronic, or subclinical course. Although effective
live-attenuated vaccines are available, pigs are not vaccinated
against CSFV in the European Union (EU) because vacci-
nated and infected pigs are serologically indistinguishable.
Outbreaks of classical swine fever (CSF) in the EU are con-
trolled by eradication of all pigs from infected farms and farms
in the vicinity. Because of this strategy, more than 10 million
pigs had to be killed and destroyed during the 1997 to 1998
CSF epizootic in The Netherlands at a cost of more than 2
billion U.S. dollars (18). It is for this reason that there is a great
demand for a marker vaccine which can provide protective
immunity and which induces an antibody response in the vac-
cinated pigs which can be distinguished from the antibody
response caused by a natural CSFV infection.
Pestiviruses are enveloped, plus-stranded RNA viruses
whose genome comprises one long open reading frame (4, 14,
15). Translation into a hypothetical polyprotein is accompa-
nied by processing into mature proteins. The structural pro-
teins include a nucleocapsid protein, C, and three envelope
glycoproteins, Erns, E1, and E2 (23). Envelope proteins Erns
and E2 are able to induce neutralizing antibodies (3, 9, 10).
Glycoprotein E2 is a good candidate to incorporate in a
vaccine because it is the most immunogenic protein of pesti-
viruses and elicits high titers of neutralizing antibodies after
infection (20, 26). Vaccination of target animals with E2 has
been shown to give protection against a lethal homologous
challenge (2, 9). When E2 is used for vaccination of pigs,
serological diagnosis of a natural pestivirus infection in pigs
has to be performed with a second antigenic viral protein. For
this purpose the Erns glycoprotein can be used as an antigen in
a diagnostic test. This is called the diva vaccine or marker
vaccine approach (24). Obviously, the application of these
marker vaccines depends on sensitive tests and, for CSFV, the
test also has to be very specific because pigs can be infected
with the other antigenically closely related pestiviruses: BVDV
and BDV. The diagnostic test for a CSFV marker vaccine
should therefore detect CSFV-specific antibodies only and no
other pestivirus-cross-reactive antibodies. A serological test
based on epitopes present on the complete Erns protein has
been developed (A. J. de Smit, G. van de Wetering, E. C.
Colijn, M. Hulst, J. A. Kramps, A. van der Blink, and R. J. M.
Moormann, unpublished data). In this study we describe a new
test which is based on a peptide containing a different epitope,
located on a small C-terminal fragment of the Erns protein.
MATERIALS AND METHODS
Peptide synthesis. Peptides were selected from the C-terminal region, (resi-
dues 191 to 227) of CSFV Erns, strain Alfort 187, BVDV Erns, strain M96751, and
BDV, strain X818 (1, 4, 19). Peptide sequences were as follows: CSFV, acetyl-
ENARQGAARV TSWLGRQLRI AGKRLEGRSK TWFGAYA-COOH and
biotin-ENARQGAARV TSWLGRQLRI AGKRLEGRSK TWFGAYA-COOH;
BVDV, acetyl-EGARQGTAKL TTWLGKQLGI LGKKLENKSK TWFGAYA-
COOH and biotin-EGARQGTAKL TTWLGKQLGI LGKKLENKSK TWF-
GAYA-COOH; BDV, biotin-ENARQGAAKL TSWLGKQLGI MGKKLEHKSK
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TWFGANA-COOH. Peptides were synthesized according to standard procedures
on an Applied Biosystems 430A synthesizer using Fastmoc chemistry (6). An
extra CSFV peptide and an extra BVDV peptide, which were N-terminally
acetylated instead of biotinylated, were synthesized.
Serum samples. The following serum samples were incorporated in the study
to evaluate the peptide ELISAs. (i) Negative field serum samples (n 5 96) were
randomly obtained from slaughtered adult pigs. Sera were all tested negative in
both the CSFV E2 (5) and the pan-pestivirus antibody-specific Ceditest enzyme-
linked immunosorbent assays (ELISAs) (11, 16). (ii) Pestivirus serum antibody-
positive but CSFV-negative serum samples (n 5 96) were randomly obtained
from slaughtered adult pigs. Swine sera were tested negative in Ceditest CSFV
E2-specific ELISA and positive in the Ceditest ELISA (11, 16). (iii) CSFV
antibody-positive field serum samples (n 5 95) were obtained from a pig farm
(VR) that was infected during the CSF epizootic in The Netherlands in 1997 to
1998. Eighty-one of the 95 samples were confirmed positive in the virus neutral-
ization test, and 75 of the 95 samples were positive in the CSFV E2 ELISA. (iv)
Sequential serum samples were collected during a vaccination-and-challenge
experiment with 11 specific-pathogen-free pigs that were vaccinated with CSFV
E2 glycoprotein and challenged with virulent CSFV strain Paderborn 2 weeks
after a single vaccination with the E2 subunit vaccine. (v) A panel of swine sera
were experimentally infected with BVDV (n 5 5; sera 4 to 8). Sera 4 and 5 were
infected with BVDV, strain den Otter; sera 6 to 8 were infected with strain
Wisman. (vi) A panel of swine sera were experimentally infected with CSFV (n 5
5; sera 9 to 13). Serum 9 was infected with strain Brescia, sera 10 to 12 were
infected with weakly virulent strain van Zoelen, and serum 13 was infected with
weakly virulent strain Henken. (vii) A panel of bovine sera were experimentally
infected with BVDV (n 5 8; sera 1 to 5, r4590-51, r4590-52, and 841). Samples
1, 2, 4, and 6 were field infections, 3 was infected with strain Appel, and 5,
r4590-51, r4590-52, and 841 were infected with strain Oregon. (viii) A reference
panel was obtained from the European reference laboratory for CSFV. The
panel included sera from swine that were experimentally infected with CSFV
(n 5 14), BDV (n 5 1), or BVDV (n 5 12). Three sera were obtained from swine
with experimental mixed infections of BVDV and BDV (n 5 1) and CSFV and
BVDV (n 5 2). (ix) Pools of hyperimmunesera (HIS) against CSFV and BVDV
were obtained.
sp-ELISA. For the solid-phase peptide ELISA (sp-ELISA), a format similar to
that for the previously developed respiratory syncytial virus G peptide ELISA
(13) was chosen. One microgram of acetylated pestivirus peptide in 50 ml of
carbonate buffer (pH 9.0, 37°C) was used to coat each well of a high-binding-
capacity flat-bottom microplate (Greiner), and the wells were dried overnight.
The optimal dilution of the peptide to coat ELISA plates was chosen in such a
manner that maximum binding was obtained, as determined in a checkerboard
titration. Swine or bovine test sera were serially diluted. Wells were washed six
times between each incubation. Mouse anti-swine immunoglobulin G (IgG)
(23.3.1b) conjugated to horseradish peroxidase (HRP) (26) was diluted 1:1,000.
Rabbit anti-bovine IgG conjugated to HRP (P0159; Dako, Glostrup, Denmark)
was diluted 1:1,000. Conjugates and test sera were incubated for 1 h at 37°C in
low-salt ELISA buffer (8.1 mM Na2HPO4, 2.79 mM KH2PO4, 0.5 M NaCl, 2.68
mM KCl, 1 mM Na2EDTA, 0.05% [vol/vol] Tween 80, pH 7.2) containing 4%
horse serum. The chromogen substrate consisted of ABTS (2,29-azinobis[3-eth-
ylbenzthiazolinesulfonic acid])-H2O2. Incubation was performed for 30 min at
22°C. Optical density (OD) was measured at 405 nm (Titertek multiscan).
Liquid-phase peptide ELISA (lp-ELISA). For avidin-coated microtiter plates,
400 ng of ImmunoPure avidin (no. 21121; Pierce, Rockfort, Ill.) in 100 ml of
carbonate buffer (pH 9) was used to coat each well of a high-binding-capacity
flat-bottom microplate (Greiner). Plates were covered and incubated overnight
at 37°C. After being coated the plates were kept frozen until use.
Before use, the avidin-coated plates were incubated with 100 ml of phosphate-
buffered saline (pH 7) with 10% horse serum per well for 2 h at 37°C on a shaker.
Meanwhile, swine or bovine test serum (diluted 1:50) was incubated with a
mixture of 10 ng of biotinylated CSFV peptide and 30 ng of acetylated BVDV
peptide in 100 ml of low-salt ELISA buffer with 4% horse serum for 1 h at 37°C.
Avidin-coated plates were washed, and 100 ml of the test serum and peptide
mixture was transferred to the wells and incubated for 45 min at 37°C. Subse-
quently, plates were washed and incubated with 100 ml of mouse anti-swine IgG
(23.3.1b) conjugated to HRP (26) and diluted 1:1,000 or with rabbit anti-bovine
IgG conjugated to HRP (P0159; Dako) and diluted 1:500. The chromogen
substrate consisted of ABTS-H2O2. Incubation was performed for 30 min at
22°C. OD was measured at 405 nm (Titertek multiscan). The cutoff value was
arbitrarily chosen as an OD of 0.5, which is approximately three times the
average background of negative sera.
Detection of CSFV antibody. Detection of CSFV Erns antibodies in sera was
performed with an ELISA developed at the Institute for Animal Science and
Health (de Smit et al., unpublished data) and a commercially available ELISA
(Chekit-MARKER CSFV ELISA; Hoechst-Roussel Vet). Both ELISAs use the
same test principle, namely, “blocking” of Erns antigen in a liquid phase. ELISAs
were performed according to the manufacturer’s description. The presence of
CSFV antibodies in serum of the pigs was determined by an E2 ELISA (5) and
a pestivirus ELISA (16). Serum samples were tested for the presence of neu-
tralizing antibodies against CSFV, BVDV (strain Oregon or NADL), and BDV
(strain F) (27), with the neutralization peroxidase-linked assay (21).
RESULTS
Selection of the peptide. Two stretches of the pestivirus Erns
protein show sequence homology with RNase Rh, a new class
of microbial RNase of Rhizopus niveus, a member of the T2/S
RNase superfamily (8). The crystal structure of RNase Rh has
been determined (12), and the three-dimensional (3D) struc-
ture confirmed that both stretches with sequence homology to
Erns constitute the active site of the RNase. The alignment,
which is shown schematically in Fig. 1, showed that the 37
C-terminal residues of Erns do not align with RNase Rh and
seem to form a separate region (Langedijk et al., unpublished
data). A 3D model was built by homology modeling using the
alignment of RNase Rh and pestivirus Erns (Langedijk et al.,
unpublished data). The 3D structure of Erns residues 1 to 190
corresponds to that of the RNase domain that is similar to
RNase Rh. The C-terminal region is a separate domain that
shows similarity to membrane active peptides.
With the aid of the structural model it is possible to define
antigenic regions on the surface of the protein which can be
mimicked by single linear peptides. These would preferably be
small subdomains, which fold relatively independently. A pep-
tide consisting of the C-terminal 37 residues (191 to 227) is the
best candidate because of its location on the outer rim on the
surface of the Erns model structure, because it forms a small
functional domain which folds independently from the rest of
the protein, and because it is not masked by any potential
carbohydrates.
We have evaluated the applicability of the peptides in diag-
nostics by the development of different diagnostic assays: an
indirect ELISA in which the antigen is recognized as bound to
a solid phase and an indirect ELISA in which the antigen is
recognized in the liquid phase.
sp-ELISA. The reactivities of BVDV-positive swine sera
(sera 4 to 8) and CSFV-positive swine sera (sera 9 to 13) were
tested for reactivity in the CSFV sp-ELISA and the BVDV
sp-ELISA (Fig. 2a and b). The reactivities of bovine sera 1 to
5, r4590-51, r4590-52, and 841 were tested in the CSFV sp-
ELISA and the BVDV sp-ELISA (Fig. 2c and d).
FIG. 1. Schematic representation of alignment of pestivirus Erns
with RNase Rh, which indicates the modular organization of Erns. Erns
consists of an RNase domain (dotted) and a C-terminal membrane
active domain (black). The C-terminal domain (residues 191 to 227) is
used as the antigen in the developed ELISA. Checkered boxes,
strongly homologous RNase active-site domains; ellipses, potential
glycosylation sites.
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Reactivities of the sera with the peptides were good, which
suggests that the peptides indeed correspond to an immuno-
dominant region of Erns. This agrees with the prediction of the
immunodominant character of the subdomain. However, the
CSFV sera and the BVDV sera are cross-reactive for both
peptides. Although the panel of CSFV-specific swine sera re-
acted better than the panel of BVDV-specific swine sera in the
CSFV ELISA (Fig. 2a), the reactivities of both panels of sera
in the BVDV ELISA were similar (Fig. 2b). Similarly, the
panel of BVDV-specific bovine sera showed high reactivity in
the BVDV peptide ELISA (Fig. 2d), but the sera also cross-
reacted considerably in the CSFV ELISA (Fig. 2c).
lp-ELISA. Because of the high cross-reactivity in the sp-
ELISA, an ELISA in which the antigen was recognized in the
liquid phase (lp-ELISA) was developed in order to measure
specific binding. Moreover, by labeling the homologous pep-
tide of the pestivirus of interest (CSFV peptide), an unlabeled
heterologous peptide of the cross-reactive pestivirus (BVDV
peptide) could be used to block unspecific cross-reactivity.
In the lp-ELISA for detection of antibodies against CSFV,
the test serum was incubated with a mixture of biotinylated
CSFV peptide and acetylated BVDV peptide (without biotin).
Most likely, CSFV-specific antibodies preferentially bind the
biotinylated CSFV peptide and BVDV-specific antibodies
preferentially bind the nonbiotinylated BVDV peptide. Subse-
quently, the mixture was transferred to an avidin-coated mi-
crotiter plate and biotinylated CSFV peptide together with the
specific antibodies was caught by avidin. The antibodies com-
plexed to the biotinylated CSFV peptide can be detected with
an antiswine-peroxidase conjugate and subsequent incubation
with substrate.
The reactivities of BVDV antibody-positive swine sera (sera
4 to 8) and CSFV-positive swine sera (sera 9 to 13) were tested
in the CSFV lp-ELISA (Fig. 3). This test format showed a high
specificity compared with that for the sp-ELISA (compare Fig.
2a with 3a). Next, the reactivities of BVDV antibody-positive
bovine sera were tested in the CSFV lp-ELISA (compare Fig.
2c with 3b).
To determine the specificity of the lp-ELISA, 96 pestivirus-
specific antibody-negative field serum samples were tested in
the lp-ELISA for CSFV Erns antibody. Only 2 of 96 samples
showed a positive response (cutoff was chosen arbitrarily as an
OD of .0.5). Based on these limited data with these small
serum panels, the specificity of the lp-ELISA for CSFV Erns
antibody amounts to 98% (94/96 3 100%) (Fig. 4).
To determine the pestivirus type specificity of the lp-ELISA,
96 field sera that contain antibodies directed against pestivi-
ruses other than CSFV (BVDV and BDV) were tested in the
lp-ELISA. Only 2 of 96 samples showed a positive response
(OD . 0.5). Based on these data, the relative specificity of the
lp-ELISA for CSFV Erns antibody in non-CSFV pestivirus-
positive sera approximates 98% (94/96 3 100%) (Fig. 4).
To determine the sensitivity of the lp-ELISA, 95 positive
field serum samples (of which 81 were confirmed positive by a
CSFV neutralization test) from a CSFV-infected farm (VR)
obtained during the CSF epizootic in The Netherlands in 1997
FIG. 2. (a) Reactivities (OD) in CSFV sp-ELISA of dilutions of BVDV-specific swine sera (4-b to 8-b), CSFV-specific swine sera (9-c to 13-c),
and CSFV-specific HIS. (b) Reactivities in BVDV sp-ELISA of dilutions of BVDV-specific swine sera (4-b to 8-b), CSFV specific swine sera (9-c
to 13-c) and CSFV-specific HIS. (c) Reactivities in CSFV sp-ELISA of dilutions of BVDV-specific bovine sera (1 to 5, r4590-51, r4590-52, and 841)
and BVDV-specific HIS. (d) Reactivities in BVDV sp-ELISA of dilutions of BVDV-specific bovine sera (1 to 5, r4590-51, r4590-52, and 841) and
BVDV-specific HIS. Blank, negative control serum.
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to 1998 were tested in the lp-ELISA. All serum samples
showed a positive response (OD . 0.5). Based on these limited
data, the relative sensitivity of the lp-ELISA for CSFV anti-
bodies amounts to 100% (Fig. 4).
An interesting application of the lp-ELISA would be a di-
agnostic test that can be used to detect CSFV infection of
E2-vaccinated pigs. Therefore, sera of E2-vaccinated pigs
should be unreactive in the lp-ELISA and should be positive if
pigs become infected after a CSFV challenge. Successive se-
rum samples that were collected during a challenge experiment
with 11 E2-vaccinated pigs that were infected with CSFV were
tested in the lp-ELISA (Fig. 5). The results show that all sera
but one from E2-vaccinated pigs were negative prior to CSFV
challenge. All animals (except 1) seroconverted 14 to 28 days
after challenge. The peptide ELISA detected more serocon-
versions 21 days after challenge (9 out of 11) than the Erns-
based ELISA (4 out of 12) (de Smit et al., unpublished data).
Finally, the performance of the lp-ELISA was compared
with that of the E2-based Ceditest ELISA and two other Erns-
based ELISAs (see Materials and Methods). The reactivities of
a panel of European reference sera (see Materials and Meth-
ods) were tested in all four ELISAs (Table 1). Although the
E2-based Ceditest ELISA was superior (one false negative),
the lp-ELISA performed better (three false negatives) than the
other ELISAs, which were based on epitope blocking using
complete Erns (five false negatives, one false positive and one
false negative, and six false positives).
To illustrate the compatibility of the peptide ELISA with
other pestiviruses, the CSFV-specific peptide ELISA was
changed into a BVDV ELISA and a BDV ELISA by exchang-
ing the biotinylated CSFV peptide for a biotinylated BVDV
peptide or a biotinylated BDV peptide, respectively, and ex-
changing the acetylated BVDV peptide for the acetylated
CSFV peptide. The amount of peptide used was the same as
that for the CSFV lp-ELISA, and all assay conditions were
kept similar. The panel of swine sera that were experimentally
infected with BVDV (n 5 5; sera 4 to 8) or CSFV (n 5 5; sera
9 to 13) were tested in the three different lp-ELISAs for the
three different pestivirus types. Table 2 shows that BVDV-
positive sera react best in the BVDV-specific peptide ELISA
and that the CSFV-positive sera react best in the CSFV ELISA
although the CSFV sera cross-react to some extent with the
BVDV peptide. As expected on the basis of the sequence
homology, the BVDV and BDV ELISAs show less differenti-
ation. The BVDV and BDV ELISAs both contained acetylated
CSFV peptide as the competing antigen. Some improvement
may be possible when acetylated BDV and BVDV peptides are
used as competing antigens in the BVDV and BDV ELISAs,
respectively.
DISCUSSION
The use of peptides as antigens in serological diagnosis has
major advantages because peptides are cheap and easy to pro-
duce in a reproducible manner. However, peptide-based or
single-epitope-based diagnostics may lack sensitivity because
of the lack of antigenic information. Most peptides that have
been used in serology represent continuous epitopes because it
is difficult to detect antibodies against complex discontinuous
epitopes using small linear peptides and because it is difficult to
predict discontinuous epitopes based on the amino acid se-
quence of a protein. In addition, it is difficult to mimic the
FIG. 3. (a) Reactivities (OD) in CSFV lp-ELISA of dilutions of
BVDV-specific swine sera (4 to 8) and CSFV-specific swine sera (9 to
13) and CSFV-specific HIS. (b) Reactivities in CSFV lp-ELISA of
dilutions of BVDV-specific bovine sera (1 to 6, r4590-51, r4590-52, and
841) and BVDV-specific HIS.
FIG. 4. Reactivities of several panels of sera in the CSFV lp-
ELISA, performed as described in Materials and Methods. Negative
field serum samples (n 5 96) were randomly obtained from slaugh-
tered adult pigs and were all tested negative in standard pestivirus
ELISA. Pestivirus-positive but CSFV-negative serum samples (n 5 96)
were randomly obtained from slaughtered adult pigs. CSFV-positive
field serum samples (n 5 95) were obtained from an infected farm
(VR) that was infected during the CSF epizootic in The Netherlands
in 1997 to 1998.
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antigenic surface of large globular proteins accurately with a
small linear peptide. The choice and design of the peptide are
of major importance for a successful peptide ELISA. We have
shown previously that a structure-based approach for the se-
lection of a candidate antigenic peptide can be successful and
can even offer antigenic peptides superior to the complete
surface protein (13). The same approach of sequence analysis
and homology modeling was used for pestivirus Erns to identify
a region that can be used for the structure-based design of
antigenic peptides. In this study we developed an ELISA which
is based on a fragment of the Erns protein which may be a
small, independently folding, biologically active protein mod-
ule. Erns can be considered an RNase domain with an inde-
pendent C-terminal domain of 37 residues, which is responsi-
ble for translocating the RNase domain across the plasma
membrane (Langedijk et al., submitted). Analysis of the hypo-
thetical Erns structure showed that this C-terminal domain
would be the best peptide candidate to harbor intact epitopes.
Peptides based on the C-terminal domains of CSFV and
BVDV, with a length of 37 residues, were synthesized and
tested for antigenicity. As expected, the peptides appeared to
harbor an immunodominant epitope(s). Most pestivirus-posi-
tive sera reacted with the peptides, but, due to the high ho-
mology and conserved mutations, the sp-ELISA was not specific
for pestivirus types. Although the peptide is immunodominant,
the intrapestivirus homology of 70% and the conserved nature
of the nonidentical residues posed a serious cross-reactivity
problem. To solve this problem, an ELISA in which the anti-
genic peptide was recognized in liquid phase and in which
antibodies specific for the other pestivirus were blocked with
the homologous peptide was developed. After optimization of
the specific peptide and blocking-peptide concentrations and
incubation time, an ELISA that showed good specificity and
that was comparably specific to, or even more specific than, the
existing ELISAs based on complete Erns was established. This
result is remarkable when the variation between CSFV strains
within the peptide (approximately 85% homology) and the
homology between pestivirus types (70%) are compared. Only
four residues (11%), at positions 9, 10, 21, 28 of the peptide,
are unique for all CSFV strains. Despite these seemingly dif-
ficult conditions, the peptide ELISA is surprisingly specific and
is able to detect CSFV antibodies against all tested strains
(Table 1). It remains to be seen how the peptide ELISA per-
forms for very distinct CSFV strains, which have some resem-
blance with other pestiviruses. If such results are inconclusive,
the OD obtained in the CSFV peptide ELISA can be com-
pared with the OD obtained in the BVDV peptide ELISA
(Table 2). The highest OD will be indicative of the virus re-
sponsible for infection. Because the peptide ELISA detects
antibodies to a different epitope than the existing ELISAs
based on complete Erns, it can also be used as a confirmation
test for Erns-specific antibodies. When new genetic sequence
information about the circulating antigenic subpopulations is
gathered, the peptides in the ELISA can be modified easily
when the circumstances call for another antigen.
It is very likely that the lp-ELISA can be optimized further
when it is changed into an antibody-blocking format like that
of the other three ELISAs in Table 1.
The peptide ELISA is less sensitive than the E2-based
ELISA (Table 1). Perhaps the peptide sequence did not match
the sequence of the infecting virus strain, but it is also likely
that the E2 protein is more immunodominant. However, this
FIG. 5. Reactivity of successive serum samples collected during a vaccination-and-challenge experiment in the CSFV lp-ELISA. Eleven pigs
were vaccinated with E2 14 days before challenge. dpc, days postchallenge.
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E2 ELISA cannot be used to differentiate between E2-vacci-
nated and infected animals. During screening we noticed that
some individual animal sera react differently in the E2 and Erns
ELISAs. Some sera reacted in the Erns ELISA or Erns peptide
ELISA and not in the E2 ELISA and vice versa. For instance,
all CSFV antibody-positive field sera (95) were tested positive
with the lp-ELISA although only 81 were confirmed positive
with the virus neutralization test. This is not understood. We
know that virus neutralization titers always correspond to an-
ti-E2 antibody titers. Therefore, it is possible that, for some
reason, antibodies against the Erns peptide appear sooner, or
more frequently, than anti-E2 antibodies in this particular
case. Both ELISAs may be reliable tests for screening at a herd
level, which is a common practice with outbreaks. The lp-
ELISA also performs well in detecting infections of E2-vacci-
nated animals. Although the replication of CSFV in these
vaccinated animals is very low due to the presence of neutral-
izing antibodies, it is possible to detect virus-specific serocon-
version in 10 out of 11 animals (Fig. 5).
In conclusion, a structure-based approach was used to de-
velop a very sensitive and specific CSFV peptide ELISA which
uses an unlabeled peptide to block cross-reactive antibodies
and which can be used to detect CSFV infections in E2-vacci-
nated pigs.
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